The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents

February 6, 2013
Otsuka Pharmaceutical announced that the European Medicines Agency has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older.
Otsuka Pharmaceutical